Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03064854
Recruitment Status : Completed
First Posted : February 27, 2017
Last Update Posted : September 13, 2021
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : July 28, 2021
Actual Study Completion Date : August 11, 2021